Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin With or Without Saxagliptin in CKD Patients With Type 2 Diabetes and Albuminuria on ACEi/ARB
jRCT2080223076Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), diabetic glomerulosclerosis and 1 more comparing Dapagliflozin 10 mg, Dapagliflozin 10 mg + Saxagliptin 2.5 mg and Placebo (3 arms). Started Jan 2016; status: completed.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)diabetic glomerulosclerosisalbuminuria
Beyond the preview
Go deeper on jRCT2080223076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223076.